$69 postpage LB

Nyrada Reported Encouraging Preclinical Results In Cholesterol-Lowering Drug Study, Stock Zooms Up by 34%

  • July 06, 2020 01:12 PM AEST
  • Team Kalkine

Australian preclinical-stage drug discovery and development company, Nyrada Inc. (ASX: NYR), in its cholesterol-lowering drug development program to treat hypercholesterolemia, made a big step forward towards replacing expensive current injections with the first-ever oral pill.

Gold MTF non-AMP

Nyrada’s Cholesterol-lowering study indicates that in healthy human white blood cells, NYR’s PCSK9 inhibitor (NYX-PCSK9i) demonstrates equivalency to the two FDA approved, marketed monoclonal PCSK9 antibody drugs, Repatha® and Praluent®, the combined FY2019 sales of which was over US$900 million.

Significantly, the results were confirmed both with and without the presence of a statin (Mevastatin), unlocking the potential to develop combined PCSK9-statin single-pill treatment for high LDL cholesterol.


The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK